- Home
- DXLG vs VNRX Comparison
DXLG vs VNRX Comparison
Compare DXLG & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXLG | VNRX |
|---|---|---|
| Founded | 1976 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 38.2M |
| IPO Year | 1987 | N/A |
Fundamental Metrics
Financial Performance| Metric | DXLG | VNRX |
|---|---|---|
| Price | $1.12 | $0.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.50 | ★ $3.17 |
| AVG Volume (30 Days) | 70.8K | ★ 2.6M |
| Earning Date | 12-11-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $447,744,000.00 | $1,472,007.00 |
| Revenue This Year | N/A | $55.33 |
| Revenue Next Year | $3.95 | $493.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.48 |
| 52 Week Low | $0.88 | $0.27 |
| 52 Week High | $3.10 | $0.94 |
Technical Indicators
Market Signals| Indicator | DXLG | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 65.07 | 35.58 |
| Support Level | $0.90 | $0.27 |
| Resistance Level | $1.00 | $0.33 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 74.29 | 31.95 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.